ArticleRevista espanola de salud publica2019
[Prevalence of ten Immune-mediated inflammatory diseases (IMID) in Spain].
Article in Revista espanola de salud publica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Pooled it
- UV Protection Habits and Preferences in Patients With Distinct Cutaneous Immune-Mediated Inflammatory Diseases.Photodermatology, photoimmunology & photomedicine · 2026Observational
- Impaired Macrophage Efferocytosis: Shared Mechanisms and Therapeutic Implications in Immune-Mediated Inflammatory Diseases.Journal of inflammation research · 2026Review
- Demographic and Clinical Characteristics, Patterns of Treatment, Quality of Life, and Resource Consumption Associated with the Management of Patients with Moderate to Severe Psoriasis in Clinical Practice in Spain: The SUMMER Project.Dermatology and therapy · 2026Article
- Mycobiota and Antifungal Antibodies as Emerging Targets for the Diagnosis and Prognosis of Human Diseases.Journal of fungi (Basel, Switzerland) · 2025Review
- Unmet needs in adult patients with ulcerative colitis in Spain: a real-world Adelphi Disease Specific Programme study.Therapeutic advances in gastroenterology · 2025Article
- Global Trends and Future Predictions of Psoriasis Burden: Insights from the GBD 2021 Study.Psoriasis (Auckland, N.Z.) · 2025Article
- Article
- Analysis of Sociodemographic and Clinical Characteristics of Inflammatory Bowel Disease in Catalonia Based on SIDIAP.Journal of clinical medicine · 2024Article
- The Impact of Shared Assistance between Dermatology and Internal Medicine on Patients with Psoriasis.Journal of clinical medicine · 2024Article
- Contraceptive Recommendations for Women with Immune-Mediated Inflammatory Diseases: A Delphi Consensus.Advances in therapy · 2024Article
- Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain.Life (Basel, Switzerland) · 2024Article
- Impact of an Intervention to Promote the Vaccination of Patients with Inflammatory Bowel Disease.Vaccines · 2023Article
- Association betweenHeliyon · 2023Article
- The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease.Life (Basel, Switzerland) · 2023Review
- The effect of an anti-inflammatory diet on chronic pain: a pilot study.Frontiers in nutrition · 2023Article
- Flare-Ups in Crohn's Disease: Influence of Stress and the External Locus of Control.International journal of environmental research and public health · 2022Article
- Review
- Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare.Frontiers in immunology · 2022Observational
- A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib.European journal of hospital pharmacy : science and practice · 2021Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveImmune-mediated inflammatory diseases (IMID) are chronic and highly disabling diseases that share inflammatory sequences and immunological dysregulations. Considered as a disease in itself, the prevalence of IMID is virtually unknown. The aim of this study was to assess the prevalence of 10 selected UDI, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, hidradenitis suppurativa, sarcoidosis and uveitis in Spain.
methodscross-sectional epidemiological study of point prevalence was made. This study was carried out through a series of computerized interviews in households chosen at random in 17 autonomous communities in Spain. A structured questionnaire was used to determine the frequency of diagnosis and the concurrence of 10 IMID in the respondents and other individuals belonging to the same family nucleus. The point prevalence estimates were used and compared with the objective of determining the frequency of IMID by age, sex and communities. The data were processed using Excel 2016 (Microsoft, Redmond, WA, USA) and the SPSS V.019 system (IBM Corp. Armonk, NY, USA) for statistical analysis using the usual statistical tests in this type of studies.
resultsOf the 7,980 respondents, 510 were diagnosed with an IMID, representing a cross-sectional study of 6.39% (95% CI: 6.02-6.76). One, two, three or more members of the family were affected in 87.2%, 7.8% and 5% of positive relatives in IMID, respectively. The most recurrent diseases were psoriasis (2.69% [95% CI: 2.32-3.06]) and rheumatic arthritis (1.07% [95% CI: 0.70-1.44]). There were differences in prevalence due to sex (p = 0.004) and age (p = 0.000). No significant differences were identified related to geographic location (p = 0.819). Attendance of at least 2 IMID was reported in 8.9% of respondents.
conclusionsThe overall prevalence was of the IMID studied was 6.39%, psoriasis being the most frequent with 2.69%. This study constitutes an initial step to consider IMID as an independent disease within the health system..
Indexed as
Identifiers
30907380PMC11583153W2980759941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.